Please enable JavaScript to continue using this application.

Compare $CHRS vs $CNTN | Chartloom

Compare

$CHRS vs $CNTN

Coherus Oncology Inc · Canton Strategic Holdings Inc

CHRS

Coherus Oncology Inc

CNTN

Canton Strategic Holdings Inc

Compare $CHRS vs $CNTN

Comparing Coherus Oncology Inc and Canton Strategic Holdings Inc

CHRSCoherus Oncology Inc

CNTNCanton Strategic Holdings Inc

CHRSCoherus Oncology Inc

Market cap

$165M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

2.04x

Rev growth (TTM)

-64.3%

YTD performance

-21.9%

52W performance

-39.2%

FCF yield

-112.7%

CNTNCanton Strategic Holdings Inc

Market cap

$163M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-37.6%

52W performance

-33.6%

FCF yield

-97.9%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

CHRS

CNTN

Detailed metrics comparison

CHRS

Coherus Oncology Inc

CNTN

Canton Strategic Holdings Inc

Market Cap

CHRS$165M

CNTN$163M

Enterprise Value

CHRS$134M

CNTN$125M

Price

CHRS$1.07

CNTN$2.11

P/E Ratio

CHRSN/A

CNTNN/A

P/S Ratio

CHRS3.24x

CNTN108.78x

EV/Sales

CHRS2.63x

CNTN83.88x

EV/EBITDA

CHRS2.57x

CNTN0.00x

P/B Ratio

CHRS2.95x

CNTN0.39x

P/FCF Ratio

CHRSN/A

CNTNN/A

EV/FCF

CHRS-0.72x

CNTN-0.79x

PEG Ratio

CHRSN/A

CNTNN/A

Forward P/E (NTM)

CHRSN/A

CNTNN/A

Forward P/S (NTM)

CHRS2.04x

CNTNN/A

Revenue (TTM)

CHRS$51M

CNTN$1M

Revenue Growth (YoY)

CHRS-64.3%

CNTNN/A

Forward Rev Growth

CHRS67.8%

CNTN0.0%

Gross Margin (TTM)

CHRS68.9%

CNTN0.0%

Operating Margin (TTM)

CHRS0.0%

CNTN0.0%

EBITDA Margin (TTM)

CHRS-288.0%

CNTN-1120.1%

Net Margin (TTM)

CHRS-259.4%

CNTN-6559.1%

FCF Margin (TTM)

CHRS-365.2%

CNTN-10651.0%

Net Income (TTM)

CHRS$-132M

CNTN$-98M

FCF (TTM)

CHRS$-186M

CNTN$-159M

EPS (TTM)

CHRS-$0.85

CNTN-$0.45

ROE (TTM)

CHRS-18336.0%

CNTN-2954.0%

ROA (TTM)

CHRS-4290.0%

CNTN-2342.0%

ROIC (TTM)

CHRS-10716.0%

CNTN-2953.0%

Cash

CHRS$83M

CNTN$37M

Debt

CHRS$52M

CNTN$0

Net Cash/Debt

CHRS$31M

CNTN$37M

Current Ratio (TTM)

CHRS1.77x

CNTN15.70x

Quick Ratio (TTM)

CHRS1.58x

CNTN14.45x

Debt/Equity (TTM)

CHRS0.85x

CNTN0.00x

Debt/Assets (TTM)

CHRS0.0%

CNTN0.0%

Interest Coverage (TTM)

CHRSN/A

CNTNN/A

Net Debt/EBITDA (TTM)

CHRS0.00x

CNTN0.00x

Beta

CHRS0.99

CNTN1.52

52W Performance

CHRS-39.2%

CNTN-33.6%

YTD Performance

CHRS-21.9%

CNTN-37.6%

% from 52W High

CHRS-59.1%

CNTN-69.4%

% from 52W Low

CHRS9.9%

CNTN20.6%

Asset Turnover (TTM)

CHRS0.17x

CNTN0.00x

FCF Yield (TTM)

CHRS-112.7%

CNTN-97.9%

Earnings Yield (TTM)

CHRS-80.1%

CNTN-60.3%

Dividend Yield (TTM)

CHRSN/A

CNTNN/A

Rule of 40

CHRS-429.5

CNTN-10,651.0

EV/GP/RG

CHRS0.05

CNTNN/A

Ticker research

View CHRS research View CNTN research

Metric	CHRS Coherus Oncology Inc	CNTN Canton Strategic Holdings Inc
Market & Valuation
Market Cap	$165M	$163M
Enterprise Value	$134M	$125M
Price	$1.07	$2.11
P/E Ratio	N/A	N/A
P/S Ratio	3.24x	108.78x
EV/Sales	2.63x	83.88x
EV/EBITDA	2.57x	0.00x
P/B Ratio	2.95x	0.39x
P/FCF Ratio	N/A	N/A
EV/FCF	-0.72x	-0.79x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	2.04x	N/A
Revenue & Growth
Revenue (TTM)	$51M	$1M
Revenue Growth (YoY)	-64.3%	N/A
Forward Rev Growth	67.8%	0.0%
Profitability
Gross Margin (TTM)	68.9%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-288.0%	-1120.1%
Net Margin (TTM)	-259.4%	-6559.1%
FCF Margin (TTM)	-365.2%	-10651.0%
Net Income (TTM)	$-132M	$-98M
FCF (TTM)	$-186M	$-159M
EPS (TTM)	-$0.85	-$0.45
ROE (TTM)	-18336.0%	-2954.0%
ROA (TTM)	-4290.0%	-2342.0%
ROIC (TTM)	-10716.0%	-2953.0%
Financial Health
Cash	$83M	$37M
Debt	$52M	$0
Net Cash/Debt	$31M	$37M
Current Ratio (TTM)	1.77x	15.70x
Quick Ratio (TTM)	1.58x	14.45x
Debt/Equity (TTM)	0.85x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.99	1.52
52W Performance	-39.2%	-33.6%
YTD Performance	-21.9%	-37.6%
% from 52W High	-59.1%	-69.4%
% from 52W Low	9.9%	20.6%
Efficiency & Yields
Asset Turnover (TTM)	0.17x	0.00x
FCF Yield (TTM)	-112.7%	-97.9%
Earnings Yield (TTM)	-80.1%	-60.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-429.5	-10,651.0
EV/GP/RG	0.05	N/A
Ticker research	View CHRS research	View CNTN research

Valuation

P/S Ratio

CHRS

3.24x

CNTN

108.78x

EV/FCF

CNTN

-0.79x

CHRS

-0.72x

Growth & revenue

Revenue Growth TTM

CHRS

-64.3%

Forward Revenue Growth

CHRS

67.8%

CNTN

0.0%

Profitability & performance

Gross Margin

CHRS

68.9%

CNTN

0.0%

ROE

CNTN

-2954.0%

CHRS

-18336.0%

FCF Yield %

CNTN

-97.9%

CHRS

-112.7%

52-Week Performance

CNTN

-33.6%

CHRS

-39.2%

Detailed metrics comparison

CHRS

Coherus Oncology Inc

CNTN

Canton Strategic Holdings Inc

Market Cap

CHRS$165M

CNTN$163M

Enterprise Value

CHRS$134M

CNTN$125M

Price

CHRS$1.07

CNTN$2.11

P/E Ratio

CHRSN/A

CNTNN/A

P/S Ratio

CHRS3.24x

CNTN108.78x

EV/Sales

CHRS2.63x

CNTN83.88x

EV/EBITDA

CHRS2.57x

CNTN0.00x

P/B Ratio

CHRS2.95x

CNTN0.39x

P/FCF Ratio

CHRSN/A

CNTNN/A

EV/FCF

CHRS-0.72x

CNTN-0.79x

PEG Ratio

CHRSN/A

CNTNN/A

Forward P/E (NTM)

CHRSN/A

CNTNN/A

Forward P/S (NTM)

CHRS2.04x

CNTNN/A

Revenue (TTM)

CHRS$51M

CNTN$1M

Revenue Growth (YoY)

CHRS-64.3%

CNTNN/A

Forward Rev Growth

CHRS67.8%

CNTN0.0%

Gross Margin (TTM)

CHRS68.9%

CNTN0.0%

Operating Margin (TTM)

CHRS0.0%

CNTN0.0%

EBITDA Margin (TTM)

CHRS-288.0%

CNTN-1120.1%

Net Margin (TTM)

CHRS-259.4%

CNTN-6559.1%

FCF Margin (TTM)

CHRS-365.2%

CNTN-10651.0%

Net Income (TTM)

CHRS$-132M

CNTN$-98M

FCF (TTM)

CHRS$-186M

CNTN$-159M

EPS (TTM)

CHRS-$0.85

CNTN-$0.45

ROE (TTM)

CHRS-18336.0%

CNTN-2954.0%

ROA (TTM)

CHRS-4290.0%

CNTN-2342.0%

ROIC (TTM)

CHRS-10716.0%

CNTN-2953.0%

Cash

CHRS$83M

CNTN$37M

Debt

CHRS$52M

CNTN$0

Net Cash/Debt

CHRS$31M

CNTN$37M

Current Ratio (TTM)

CHRS1.77x

CNTN15.70x

Quick Ratio (TTM)

CHRS1.58x

CNTN14.45x

Debt/Equity (TTM)

CHRS0.85x

CNTN0.00x

Debt/Assets (TTM)

CHRS0.0%

CNTN0.0%

Interest Coverage (TTM)

CHRSN/A

CNTNN/A

Net Debt/EBITDA (TTM)

CHRS0.00x

CNTN0.00x

Beta

CHRS0.99

CNTN1.52

52W Performance

CHRS-39.2%

CNTN-33.6%

YTD Performance

CHRS-21.9%

CNTN-37.6%

% from 52W High

CHRS-59.1%

CNTN-69.4%

% from 52W Low

CHRS9.9%

CNTN20.6%

Asset Turnover (TTM)

CHRS0.17x

CNTN0.00x

FCF Yield (TTM)

CHRS-112.7%

CNTN-97.9%

Earnings Yield (TTM)

CHRS-80.1%

CNTN-60.3%

Dividend Yield (TTM)

CHRSN/A

CNTNN/A

Rule of 40

CHRS-429.5

CNTN-10,651.0

EV/GP/RG

CHRS0.05

CNTNN/A

Ticker research

View CHRS research View CNTN research

Metric	CHRS Coherus Oncology Inc	CNTN Canton Strategic Holdings Inc
Market & Valuation
Market Cap	$165M	$163M
Enterprise Value	$134M	$125M
Price	$1.07	$2.11
P/E Ratio	N/A	N/A
P/S Ratio	3.24x	108.78x
EV/Sales	2.63x	83.88x
EV/EBITDA	2.57x	0.00x
P/B Ratio	2.95x	0.39x
P/FCF Ratio	N/A	N/A
EV/FCF	-0.72x	-0.79x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	2.04x	N/A
Revenue & Growth
Revenue (TTM)	$51M	$1M
Revenue Growth (YoY)	-64.3%	N/A
Forward Rev Growth	67.8%	0.0%
Profitability
Gross Margin (TTM)	68.9%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-288.0%	-1120.1%
Net Margin (TTM)	-259.4%	-6559.1%
FCF Margin (TTM)	-365.2%	-10651.0%
Net Income (TTM)	$-132M	$-98M
FCF (TTM)	$-186M	$-159M
EPS (TTM)	-$0.85	-$0.45
ROE (TTM)	-18336.0%	-2954.0%
ROA (TTM)	-4290.0%	-2342.0%
ROIC (TTM)	-10716.0%	-2953.0%
Financial Health
Cash	$83M	$37M
Debt	$52M	$0
Net Cash/Debt	$31M	$37M
Current Ratio (TTM)	1.77x	15.70x
Quick Ratio (TTM)	1.58x	14.45x
Debt/Equity (TTM)	0.85x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.99	1.52
52W Performance	-39.2%	-33.6%
YTD Performance	-21.9%	-37.6%
% from 52W High	-59.1%	-69.4%
% from 52W Low	9.9%	20.6%
Efficiency & Yields
Asset Turnover (TTM)	0.17x	0.00x
FCF Yield (TTM)	-112.7%	-97.9%
Earnings Yield (TTM)	-80.1%	-60.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-429.5	-10,651.0
EV/GP/RG	0.05	N/A
Ticker research	View CHRS research	View CNTN research